The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.

ABSTRACT:

Background

Daratumumab (Dara), a humanized IgGκ monoclonal antibody targeting CD38, has shown significant efficacy in the treatment of multiple myeloma (MM). However, its impact on myeloma bone disease (MBD) and skeletal-related events (SREs) remains inadequately explored. Elucidating the effect of Dara on the incidence of SREs is of considerable clinical importance for MM management.

Methods

We conducted a multicenter retrospective analysis of 164 newly diagnosed MM (NDMM) patients who received first-line treatment with or without Dara-based regimens between December 2019 and December 2023. The primary endpoint was the incidence of first SRE within 6 months. Subgroup analyses were performed based on risk stratification, baseline hypercalcemia, extramedullary disease, circul

SUBMITTER: Li X 

PROVIDER: S-EPMC12723850 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature